185 related articles for article (PubMed ID: 22691266)
1. Long-term outcome and toxicity of hypofractionated stereotactic body radiotherapy as a boost treatment for head and neck cancer: the importance of boost volume assessment.
Lee DS; Kim YS; Cheon JS; Song JH; Son SH; Jang JS; Kang YN; Kang JH; Jung SL; Yoo IeR; Jang HS
Radiat Oncol; 2012 Jun; 7():85. PubMed ID: 22691266
[TBL] [Abstract][Full Text] [Related]
2. Hypofractionated stereotactic radiotherapy using CyberKnife as a boost treatment for head and neck cancer, a multi-institutional survey: impact of planning target volume.
Yamazaki H; Ogita M; Himei K; Nakamura S; Yoshida K; Kotsuma T; Yamada Y; Fujiwara M; Baek S; Yoshioka Y
Anticancer Res; 2014 Oct; 34(10):5755-9. PubMed ID: 25275085
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response.
Jabbari S; Weinberg VK; Kaprealian T; Hsu IC; Ma L; Chuang C; Descovich M; Shiao S; Shinohara K; Roach M; Gottschalk AR
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):228-34. PubMed ID: 21183287
[TBL] [Abstract][Full Text] [Related]
4. A multicenter prospective phase II study of postoperative hypofractionated stereotactic body radiotherapy (SBRT) in the treatment of early-stage oropharyngeal and oral cavity cancers with high risk margins: the STEREO POSTOP GORTEC 2017-03 trial.
Biau J; Thivat E; Millardet C; Saroul N; Pham-Dang N; Molnar I; Pereira B; Durando X; Bourhis J; Lapeyre M
BMC Cancer; 2020 Aug; 20(1):730. PubMed ID: 32758188
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of hypofractionated stereotactic body reirradiation in head and neck cancer: Long-term follow-up of a large series.
Kress MA; Sen N; Unger KR; Lominska CE; Deeken JF; Davidson BJ; Newkirk KA; Hwang J; Harter KW
Head Neck; 2015 Oct; 37(10):1403-9. PubMed ID: 24824359
[TBL] [Abstract][Full Text] [Related]
6. Re-irradiation stereotactic body radiotherapy for spinal metastases: a multi-institutional outcome analysis.
Hashmi A; Guckenberger M; Kersh R; Gerszten PC; Mantel F; Grills IS; Flickinger JC; Shin JH; Fahim DK; Winey B; Oh K; John Cho BC; Létourneau D; Sheehan J; Sahgal A
J Neurosurg Spine; 2016 Nov; 25(5):646-653. PubMed ID: 27341054
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic body radiotherapy as boost for organ-confined prostate cancer.
Katz AJ; Santoro M; Ashley R; Diblasio F; Witten M
Technol Cancer Res Treat; 2010 Dec; 9(6):575-82. PubMed ID: 21070079
[TBL] [Abstract][Full Text] [Related]
8. Fractionated stereotactic radiotherapy as reirradiation for locally recurrent head and neck cancer.
Roh KW; Jang JS; Kim MS; Sun DI; Kim BS; Jung SL; Kang JH; Yoo EJ; Yoon SC; Jang HS; Chung SM; Kim YS
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1348-55. PubMed ID: 19117695
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic body radiation therapy for primary, recurrent, and metastatic tumors in the head-and-neck region.
Siddiqui F; Patel M; Khan M; McLean S; Dragovic J; Jin JY; Movsas B; Ryu S
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1047-53. PubMed ID: 19327895
[TBL] [Abstract][Full Text] [Related]
10. The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy.
Rwigema JC; Heron DE; Ferris RL; Andrade RS; Gibson MK; Yang Y; Ozhasoglu C; Argiris AE; Grandis JR; Burton SA
Am J Clin Oncol; 2011 Aug; 34(4):372-9. PubMed ID: 20859194
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic Body Radiation Therapy Boost After Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer: A Phase 1 Dose Escalation Study.
Hepel JT; Leonard KL; Safran H; Ng T; Taber A; Khurshid H; Birnbaum A; ; Wazer DE; DiPetrillo T
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1021-1027. PubMed ID: 27745983
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic body radiation therapy for benign spine tumors: is dose de-escalation appropriate?
Kalash R; Glaser SM; Flickinger JC; Burton S; Heron DE; Gerszten PC; Engh JA; Amankulor NM; Vargo JA
J Neurosurg Spine; 2018 Aug; 29(2):220-225. PubMed ID: 29799334
[TBL] [Abstract][Full Text] [Related]
13. Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients.
Nicosia L; Mazzola R; Rigo M; Figlia V; Giaj-Levra N; Napoli G; Ricchetti F; Corradini S; Ruggieri R; Alongi F
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2547-2554. PubMed ID: 31324979
[TBL] [Abstract][Full Text] [Related]
14. 4π noncoplanar stereotactic body radiation therapy for head-and-neck cancer: potential to improve tumor control and late toxicity.
Rwigema JC; Nguyen D; Heron DE; Chen AM; Lee P; Wang PC; Vargo JA; Low DA; Huq MS; Tenn S; Steinberg ML; Kupelian P; Sheng K
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):401-9. PubMed ID: 25482301
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
[TBL] [Abstract][Full Text] [Related]
16. Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study.
Higgins KA; Pillai RN; Chen Z; Tian S; Zhang C; Patel P; Pakkala S; Shelton J; Force SD; Fernandez FG; Steuer CE; Owonikoko TK; Ramalingam SS; Bradley JD; Curran WJ
J Thorac Oncol; 2017 Nov; 12(11):1687-1695. PubMed ID: 28919394
[TBL] [Abstract][Full Text] [Related]
17. A Randomized Phase II Trial of Prostate Boost Irradiation With Stereotactic Body Radiotherapy (SBRT) or Conventional Fractionation (CF) External Beam Radiotherapy (EBRT) in Locally Advanced Prostate Cancer: The PBS Trial (NCT03380806).
Isfahanian N; Lukka H; Dayes I; Quan K; Schnarr KL; Douvi G; Goldberg M; Wright J; Swaminath A; Chow T; Diamond K; Cutz JC; Kavsak P; Thabane L; Tsakiridis T
Clin Genitourin Cancer; 2020 Aug; 18(4):e410-e415. PubMed ID: 32265129
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic Body Radiation Therapy for Mediastinal and Hilar Lymph Node Metastases.
Shahi J; Poon I; Ung YC; Tsao M; Bjarnason GA; Malik NH; Zhang L; Louie AV; Cheung P
Int J Radiat Oncol Biol Phys; 2021 Mar; 109(3):764-774. PubMed ID: 33115687
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant stereotactic body radiotherapy±cetuximab following salvage surgery in previously irradiated head and neck cancer.
Vargo JA; Kubicek GJ; Ferris RL; Duvvuri U; Johnson JT; Ohr J; Clump DA; Burton S; Heron DE
Laryngoscope; 2014 Jul; 124(7):1579-84. PubMed ID: 24123056
[TBL] [Abstract][Full Text] [Related]
20. Dose escalation in advanced floor of the mouth cancer: a pilot study using a combination of IMRT and stereotactic boost.
Blažek T; Zděblová Čermáková Z; Knybel L; Hurník P; Štembírek J; Resová K; Paračková T; Formánek M; Cvek J; Soumarová R
Radiat Oncol; 2021 Jun; 16(1):122. PubMed ID: 34187494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
